research Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
research Tebentafusp-tebn (Kimmtra®) March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.